41100-45-2

Basic information

• Product Name: 3-ethyladamantan-1-amine
• Synonyms: 3-ethyladamantan-1-amine;1-amino-3-ethyladamantane;(3-ethyl-1-adamantyl)amine hydrochloride;(3-ethyl-1-adamantyl)amine(SALTDATA: HCl);(3-ethyl-1-adaMantyl)aMine hydrochloride (SALTDATA: HCl);1-Ethyl-3-aminoadamantane;MRZ 2/175;Memantine impurity A
• CAS NO: 41100-45-2
• Molecular Formula: C₁₂H₂₁N
• Molecular Weight: 179.301840
• Mol File: 41100-45-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 244.6 °C at 760 mmHg
• Flash Point: 97.5 °C
• Appearance: /
• Density: 1.029 g/cm³
• Vapor Pressure: 0.0301mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Hygroscopic, Room Temperature, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 10.78±0.40(Predicted)
• CAS DataBase Reference: 3-ethyladamantan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ethyladamantan-1-amine(41100-45-2)
• EPA Substance Registry System: 3-ethyladamantan-1-amine(41100-45-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 41100-45-2(Hazardous Substances Data)

Usage

Uses

3-Ethyl 3,5-Didemethyl Memantine is an impurity of Memantine (HCl salt, M218000) which is used as an antiparkinsonian and antispasmodic.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 25, p. 51, 1982 DOI: 10.1021/jm00343a010

InChI:InChI=1/C12H21N/c1-2-11-4-9-3-10(5-11)7-12(13,6-9)8-11/h9-10H,2-8,13H2,1H3

Upstream product

• 15598-87-5 3-ethyladamantane-1-ol 
• 26831-48-1 2-(adamantan-1-yl)ethyl-4-methylbenzenesulfonate 
• 6240-11-5 2-(adamant-1-yl)ethanol 
• 878-61-5 1-Bromo-3-ethyladamantane 
• 770-69-4 1-ethyladamantane 
• 60931-65-9 N-acetyl-3-ethyl-1-aminoadamantane 

Downstream Products

• 80121-67-1 3-ethyl-1-aminoadamantane hydrochloride 

Relevant articles and documents

PROCESS FOR PRODUCING 3-ETHYL-1-ADAMANTYLAMINE

PROBLEM TO BE SOLVED: To provide an industrially economical and efficient synthetic method of 3-ethyl-1-adamantylamine, which does not include a synthetic process of 1-bromo-3-ethyladamantane which uses harmful halogen and which, in a synthetic reaction of 1-amide-3-ethyladamantane, suppresses by-products and improves a yield by reducing amounts of use of an amide or an acid and a nitrile relative to adamantanes, and also remarkably reduces wastes derived from the amide or the acid and the nitrile. SOLUTION: A method for producing 3-ethyl-1-adamantylamine comprises the following steps (i) to (iii): (i) a step of obtaining a reaction mixture by reacting 3-ethyl-1-adamantanol with an acid and a nitrile in an organic solvent; (ii) a step of obtaining 1-amide-3-ethyladamantane by adding water to the reaction mixture obtained in the step (i); and (iii) a step of hydrolyzing 1-amide-3-ethyladamantane obtained in the step (ii) in the presence of an alcohol-containing solvent and an inorganic base. COPYRIGHT: (C)2015,JPO&INPIT

METHODS OF TREATING CNS DISORDERS

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.